Professionals with a history of infection confirmed by SARS-CoV-2 or who have already been diagnosed with COVID-19 prior to the study, Individuals who have not performed confirmatory tests for COVID-19, Pregnancy or breast-feeding, Non-permanence in activities in the Health Units after 6 months of enrollment in the study, Individuals with primary or acquired immunodeficiency, Individuals with malignant neoplasms, Patients on high-dose corticosteroids (equivalent to a prednisone dose of 20 mg / day or more) for more than two weeks, Patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiation therapy, among others), Individuals with autoimmune diseases, Dermatological disorders at the vaccine site or generalized, Individuals under treatment for active tuberculosis, Individuals with report of fever (axillary temperature> 38 ° C in the last 48h)

Professionals with a history of infection confirmed by SARS-CoV-2 or who have already been diagnosed with COVID-19 prior to the study, Individuals who have not performed confirmatory tests for COVID-19, Pregnancy or breast-feeding, Non-permanence in activities in the Health Units after 6 months of enrollment in the study, Individuals with primary or acquired immunodeficiency, Individuals with malignant neoplasms, Patients on high-dose corticosteroids (equivalent to a prednisone dose of 20 mg / day or more) for more than two weeks, Patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiation therapy, among others), Individuals with autoimmune diseases, Dermatological disorders at the vaccine site or generalized, Individuals under treatment for active tuberculosis, Individuals with report of fever (axillary temperature> 38 ° C in the last 48h)